A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Recruiting

Phase 2

Pembrolizumab & ILIA Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT04332874

Conditions

Sarcoma

Myxofibrosarcoma

Undifferentiated Pleomorphic Sarcoma

Alveolar Soft Part Sarcoma

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Isolated Limb Infusion

Pembrolizumab

infusion of melphalan and dactinomycin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2025-05-02.